Artigos de revistas sobre o tema "JAK/STAT inhibitors"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Veja os 50 melhores artigos de revistas para estudos sobre o assunto "JAK/STAT inhibitors".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Veja os artigos de revistas das mais diversas áreas científicas e compile uma bibliografia correta.
Jones, Dan, Justin Windham, Brian Stewart, Luis Fayad, Alma Rodriguez e Fredrick B. Hagemeister. "Differential JAK-STAT Pathway Activation in Primary Mediastinal Large B-Cell Lymphoma: Two Subgroups with Differential Cytokine Activation Patterns and Predicted Responses to Kinase Inhibitors." Blood 114, n.º 22 (20 de novembro de 2009): 968. http://dx.doi.org/10.1182/blood.v114.22.968.968.
Texto completo da fonteMalemud, Charles J. "The role of the JAK/STAT signal pathway in rheumatoid arthritis". Therapeutic Advances in Musculoskeletal Disease 10, n.º 5-6 (19 de maio de 2018): 117–27. http://dx.doi.org/10.1177/1759720x18776224.
Texto completo da fonteCacciapaglia, F., V. Venerito, S. del Vescovo, S. Stano, R. Bizzoca, D. Natuzzi, N. Lacarpia, M. Fornaro e F. Iannone. "AB0070 INHIBITION OF STAT3 IN PBMCs FROM RHEUMATOID ARTHRITIS PATIENTS: CLUES TO UNDERSTAND SELECTIVITY OF JANUS KINASE INHIBITORS". Annals of the Rheumatic Diseases 81, Suppl 1 (23 de maio de 2022): 1167.2–1168. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1997.
Texto completo da fonteCacciapaglia, F., S. Perniola, S. del Vescovo, S. Stano, R. Bizzoca, D. Natuzzi, M. Fornaro e F. Iannone. "AB0134 IN-VITRO STUDY ON THE EFFECT OF SELECTIVE Jak-INHIBITORS ON PBMCs STAT3 PHOSPHORYLATION FROM SYSTEMIC SCLEROSIS PATIENTS". Annals of the Rheumatic Diseases 81, Suppl 1 (23 de maio de 2022): 1196.3–1197. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2625.
Texto completo da fonteConzelmann, Michael, Elena Rodionova, Michael Hess, Thomas Giese, Anthony D. Ho, Peter Dreger e Thomas Luft. "Complementary JAK/STAT Signalling Is Required for the Pro-Inflammatory Effects of CD40 Ligation: Differential Effects in Human Myeloid and B Cells." Blood 110, n.º 11 (16 de novembro de 2007): 2413. http://dx.doi.org/10.1182/blood.v110.11.2413.2413.
Texto completo da fonteGalli Sanchez, Ana Paula, Tatiane Ester Aidar Fernandes e Gustavo Martelli Palomino. "The JAK-STAT Pathway and the JAK Inhibitors". Journal of Clinical Research in Dermatology 7, n.º 5 (30 de novembro de 2020): 1–6. http://dx.doi.org/10.15226/2378-1726/7/5/001128.
Texto completo da fonteRaivola, Juuli, Teemu Haikarainen, Bobin George Abraham e Olli Silvennoinen. "Janus Kinases in Leukemia". Cancers 13, n.º 4 (14 de fevereiro de 2021): 800. http://dx.doi.org/10.3390/cancers13040800.
Texto completo da fonteRaivola, Juuli, Teemu Haikarainen e Olli Silvennoinen. "Characterization of JAK1 Pseudokinase Domain in Cytokine Signaling". Cancers 12, n.º 1 (27 de dezembro de 2019): 78. http://dx.doi.org/10.3390/cancers12010078.
Texto completo da fonteBhagwat, Neha, Priya Koppikar, Outi Kilpivaara, Taghi Manshouri, Mazhar Adli, Ann Mullally, Omar Abdel-Wahab et al. "Heterodimeric JAK-STAT Activation As a Mechanism of Persistence to JAK2 Inhibitor Therapy". Blood 118, n.º 21 (18 de novembro de 2011): 122. http://dx.doi.org/10.1182/blood.v118.21.122.122.
Texto completo da fonteMeyer, Sara C., Matthew D. Keller, Priya Koppikar, Olga A. Guryanova, Maria Kleppe, Anna Sophia McKenney, William R. Sellers et al. "Type II Inhibition of JAK2 with NVP-CHZ868 Reverses Type I JAK Inhibitor Persistence and Demonstrates Increased Efficacy in MPN Models". Blood 124, n.º 21 (6 de dezembro de 2014): 160. http://dx.doi.org/10.1182/blood.v124.21.160.160.
Texto completo da fonteGorre, M., I. Jilani, H. Kantarjian, F. Giles, A. Hannah e M. Albitar. "Novel Quantitative Flow Cytometry-Based Signaling Assays Reveal a Potential Role for HSP90 Inhibitors in the Treatment of JAK2 Mutant-Positive Diseases." Blood 106, n.º 11 (16 de novembro de 2005): 3526. http://dx.doi.org/10.1182/blood.v106.11.3526.3526.
Texto completo da fonteCallus, Bernard A., e Bernard Mathey-Prevot. "Interleukin-3–Induced Activation of the JAK/STAT Pathway Is Prolonged by Proteasome Inhibitors". Blood 91, n.º 9 (1 de maio de 1998): 3182–92. http://dx.doi.org/10.1182/blood.v91.9.3182.
Texto completo da fonteCallus, Bernard A., e Bernard Mathey-Prevot. "Interleukin-3–Induced Activation of the JAK/STAT Pathway Is Prolonged by Proteasome Inhibitors". Blood 91, n.º 9 (1 de maio de 1998): 3182–92. http://dx.doi.org/10.1182/blood.v91.9.3182.3182_3182_3192.
Texto completo da fonteHashemi, David, e Neal Bhatia. "The JAK-Cytokine Interface – A Review and Update on Prospective Clinical Considerations". SKIN The Journal of Cutaneous Medicine 7, n.º 4 (17 de julho de 2023): 932–35. http://dx.doi.org/10.25251/skin.7.4.16.
Texto completo da fonteShawky, Ahmed M., Faisal A. Almalki, Ashraf N. Abdalla, Ahmed H. Abdelazeem e Ahmed M. Gouda. "A Comprehensive Overview of Globally Approved JAK Inhibitors". Pharmaceutics 14, n.º 5 (6 de maio de 2022): 1001. http://dx.doi.org/10.3390/pharmaceutics14051001.
Texto completo da fonteMusumeci, Francesca, Chiara Greco, Ilaria Giacchello, Anna Lucia Fallacara, Munjed M. Ibrahim, Giancarlo Grossi, Chiara Brullo e Silvia Schenone. "An Update on JAK Inhibitors". Current Medicinal Chemistry 26, n.º 10 (20 de junho de 2019): 1806–32. http://dx.doi.org/10.2174/0929867325666180327093502.
Texto completo da fonteSuzuki, Asuka, Toshikatsu Hanada, Keiichi Mitsuyama, Takafumi Yoshida, Shintaro Kamizono, Tomoaki Hoshino, Masato Kubo et al. "Cis3/Socs3/Ssi3 Plays a Negative Regulatory Role in Stat3 Activation and Intestinal Inflammation". Journal of Experimental Medicine 193, n.º 4 (12 de fevereiro de 2001): 471–82. http://dx.doi.org/10.1084/jem.193.4.471.
Texto completo da fonteThomas, Sally J., Katherine Fisher, Stephen Brown, John A. Snowden, Sarah Danson e Martin Zeidler. "Methotrexate Is a Suppressor of JAK/STAT Pathway Activation Which Inhibits JAK2V617F Induced Signalling". Blood 124, n.º 21 (6 de dezembro de 2014): 4577. http://dx.doi.org/10.1182/blood.v124.21.4577.4577.
Texto completo da fonteTaldaev, Amir, Vladimir R. Rudnev, Kirill S. Nikolsky, Liudmila I. Kulikova e Anna L. Kaysheva. "Molecular Modeling Insights into Upadacitinib Selectivity upon Binding to JAK Protein Family". Pharmaceuticals 15, n.º 1 (25 de dezembro de 2021): 30. http://dx.doi.org/10.3390/ph15010030.
Texto completo da fonteMoser, Bernhard, Sophie Edtmayer, Agnieszka Witalisz-Siepracka e Dagmar Stoiber. "The Ups and Downs of STAT Inhibition in Acute Myeloid Leukemia". Biomedicines 9, n.º 8 (19 de agosto de 2021): 1051. http://dx.doi.org/10.3390/biomedicines9081051.
Texto completo da fonteZhang, Xuekang, Jun Zhou, Qian Hu, Zhengren Liu, Qiuhong Chen, Wenxiang Wang, Huaigen Zhang, Qin Zhang e Yuanlu Huang. "The Role of Janus Kinase/Signal Transducer and Activator of Transcription Signalling on Preventing Intestinal Ischemia/Reperfusion Injury with Dexmedetomidine". Journal of Nanoscience and Nanotechnology 20, n.º 5 (1 de maio de 2020): 3295–302. http://dx.doi.org/10.1166/jnn.2020.16416.
Texto completo da fonteZheng, Ying, Hongwei Qin, Stuart J. Frank, Luqin Deng, David W. Litchfield, Ayalew Tefferi, Animesh Pardanani et al. "A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway". Blood 118, n.º 1 (7 de julho de 2011): 156–66. http://dx.doi.org/10.1182/blood-2010-01-266320.
Texto completo da fonteHu, Cheng-Ping, Jun-Tao Feng, Yu-Ling Tang, Jin-Qi Zhu, Min-Juan Lin e Ming-En Yu. "LIF Upregulates Expression of NK-1R in NHBE Cells". Mediators of Inflammation 2006 (2006): 1–8. http://dx.doi.org/10.1155/mi/2006/84829.
Texto completo da fonteKim, Jung Eun, Yu Jin Lee, Hye Ree Park, Dong Geon Lee, Kwan Ho Jeong e Hoon Kang. "The Effect of JAK Inhibitor on the Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells". International Journal of Molecular Sciences 21, n.º 14 (20 de julho de 2020): 5137. http://dx.doi.org/10.3390/ijms21145137.
Texto completo da fonteKarati, Dipanjan, Kakasaheb Ramoo Mahadik, Piyush Trivedi e Dileep Kumar. "The Emerging Role of Janus Kinase Inhibitors in the Treatment of Cancer". Current Cancer Drug Targets 22, n.º 3 (março de 2022): 221–33. http://dx.doi.org/10.2174/1568009622666220301105214.
Texto completo da fonteKapuria, Vaibhav, Geoffrey Bartholomeusz, Ling-Yuan Kong, William Bornmann, Zhenghong Peng, Ashutosh Pal, David Maxwell, Moshe Talpaz e Nicholas Donato. "A Novel Small-Molecule Approach To Inhibit Jak2 Tyrosine Kinase Signaling." Blood 110, n.º 11 (16 de novembro de 2007): 1556. http://dx.doi.org/10.1182/blood.v110.11.1556.1556.
Texto completo da fonteSpringuel, Lorraine, Tekla Hornakova, Elisabeth Losdyck, Fanny Lambert, Emilie Leroy, Stefan N. Constantinescu, Elisabetta Flex, Marco Tartaglia, Laurent Knoops e Jean-Christophe Renauld. "Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors". Blood 124, n.º 26 (18 de dezembro de 2014): 3924–31. http://dx.doi.org/10.1182/blood-2014-05-576652.
Texto completo da fonteSonkin, Dmitriy, Catherine Regnier, Xianhui Rong, Christie Fanton, Michael Palmer, Jocelyn Holash, Matthew Squires et al. "Identification of pSTAT5 gene signature in hematologic malignancy." Journal of Clinical Oncology 31, n.º 15_suppl (20 de maio de 2013): 7111. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.7111.
Texto completo da fonteHaysen, S., A. L. L. Nielsen, P. Qvist e T. W. Kragstrup. "POS0038 GENOMICS OF JAK-STAT SIGNALING IN VENOUS THROMBOEMBOLISM". Annals of the Rheumatic Diseases 81, Suppl 1 (23 de maio de 2022): 234.1–234. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2593.
Texto completo da fonteJeong, Ga Hee, e Ji Hyun Lee. "Dysregulated Hippo Signaling Pathway and YAP Activation in Atopic Dermatitis: Insights from Clinical and Animal Studies". International Journal of Molecular Sciences 24, n.º 24 (10 de dezembro de 2023): 17322. http://dx.doi.org/10.3390/ijms242417322.
Texto completo da fontePerner, Florian, Felix C. Saalfeld, Tina M. Schnoeder, Denise Wolleschak, Corinna Fahldieck, Satish Ranjan, Berend H. Isermann et al. "Specificity of JAK-Kinase Inhibition Determines Impact on T-Cell Function". Blood 124, n.º 21 (6 de dezembro de 2014): 1410. http://dx.doi.org/10.1182/blood.v124.21.1410.1410.
Texto completo da fontePurandare, Ashok V., Animesh Pardanani, Theresa McDevitt, Marco Gottardis, Terra Lasho, Dan You, Louis Lombardo et al. "Characterization of BMS-911543, a Functionally Selective Small Molecule Inhibitor of JAK2". Blood 116, n.º 21 (19 de novembro de 2010): 4112. http://dx.doi.org/10.1182/blood.v116.21.4112.4112.
Texto completo da fonteLim, Ken-Hong, Yu-Cheng Chang, Yi-Hao Chiang, Huan-Chau Lin, Ling Huang, Wei-Ting Wang, Ying-Wen Su, Ming-Chih Chang, Yi-Fang Chang e Caleb Gon-Shen Chen. "Acquired Resistance to JAK Inhibitors in Calr-Mutated Myeloproliferative Neoplasms". Blood 134, Supplement_1 (13 de novembro de 2019): 2970. http://dx.doi.org/10.1182/blood-2019-124420.
Texto completo da fonteRodman, Esther, Michael Emch, Elizabeth Bruinsma, Xiaonan Hou, John Weroha e John Hawse. "Abstract 1129: Interrogating JAK/STAT signaling in ovarian cancer as a potential oncogenic driver and therapeutic target". Cancer Research 82, n.º 12_Supplement (15 de junho de 2022): 1129. http://dx.doi.org/10.1158/1538-7445.am2022-1129.
Texto completo da fonteClarke, A., J. Di Paolo, B. Downie, A. Meng, N. Mollova, Y. Yu e P. Han. "P460 Evaluation of potential mechanisms underlying the safety observations of filgotinib in clinical studies in rheumatoid arthritis". Journal of Crohn's and Colitis 14, Supplement_1 (janeiro de 2020): S409. http://dx.doi.org/10.1093/ecco-jcc/jjz203.589.
Texto completo da fonteRoss, David M., Jeffrey J. Babon, Denis Tvorogov e Daniel Thomas. "Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications". Haematologica 106, n.º 5 (21 de janeiro de 2021): 1244–53. http://dx.doi.org/10.3324/haematol.2020.262691.
Texto completo da fonteMontero, Paula, Javier Milara, Inés Roger e Julio Cortijo. "Role of JAK/STAT in Interstitial Lung Diseases; Molecular and Cellular Mechanisms". International Journal of Molecular Sciences 22, n.º 12 (9 de junho de 2021): 6211. http://dx.doi.org/10.3390/ijms22126211.
Texto completo da fonteBanes, Amy K., Séan Shaw, John Jenkins, Heather Redd, Farhad Amiri, David M. Pollock e Mario B. Marrero. "Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli". American Journal of Physiology-Renal Physiology 286, n.º 4 (abril de 2004): F653—F659. http://dx.doi.org/10.1152/ajprenal.00163.2003.
Texto completo da fonteJang, Sun Hee, e Ji Hyeon Ju. "Janus kinase inhibitors for the treatment of rheumatoid arthritis". Journal of the Korean Medical Association 64, n.º 2 (10 de fevereiro de 2021): 105–8. http://dx.doi.org/10.5124/jkma.2021.64.2.105.
Texto completo da fonteSimon, Amy R., Satoe Takahashi, Mariano Severgnini, Barry L. Fanburg e Brent H. Cochran. "Role of the JAK-STAT pathway in PDGF-stimulated proliferation of human airway smooth muscle cells". American Journal of Physiology-Lung Cellular and Molecular Physiology 282, n.º 6 (1 de junho de 2002): L1296—L1304. http://dx.doi.org/10.1152/ajplung.00315.2001.
Texto completo da fonteLiu, Liqin, Violeta Yu, Jeanne Pistillo, Josie Lee, Laurie B. Schenkel, Stephanie Geuns-Meyer, Ivonne Archibeque, Angus Sinclair, Renee Emkey e Graham Molineux. "New Insights on Assessing Intra-Family Selectivity for Jak2 Inhibitors". Blood 118, n.º 21 (18 de novembro de 2011): 5150. http://dx.doi.org/10.1182/blood.v118.21.5150.5150.
Texto completo da fontePérez, Cristina, Julia Gonzalez-Rincon, Carmen Almaraz, Soraya Curiel, Nuria Garcia, Helena Pisonero, Sagrario Gomez et al. "A Role of JAK/STAT Pathway in Cutaneous T-Cell Lymphomas: Exploring Its Effects for Targeted Therapy". Blood 124, n.º 21 (6 de dezembro de 2014): 4498. http://dx.doi.org/10.1182/blood.v124.21.4498.4498.
Texto completo da fonteHindupur, Sruthi V., Sebastian C. Schmid, Jana Annika Koch, Ahmed Youssef, Eva-Maria Baur, Dongbiao Wang, Thomas Horn et al. "STAT3/5 Inhibitors Suppress Proliferation in Bladder Cancer and Enhance Oncolytic Adenovirus Therapy". International Journal of Molecular Sciences 21, n.º 3 (7 de fevereiro de 2020): 1106. http://dx.doi.org/10.3390/ijms21031106.
Texto completo da fonteBarton, Beverly E., James G. Karras, Thomas F. Murphy, Arnold Barton e Hosea F.-S. Huang. "Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines". Molecular Cancer Therapeutics 3, n.º 1 (1 de janeiro de 2004): 11–20. http://dx.doi.org/10.1158/1535-7163.11.3.1.
Texto completo da fonteWestfall, Matt, Rachael E. Hawtin, Diane Longo, Michelle Cholankeril, Reena K. Vora, Michelle Atallah, Alessandra Cesano, Steven L. Allen e Scott Z. Fields. "Functional Pathway Analysis Of JAK2 Mutated and Wild Type Myeloproliferative Neoplasms As a Tool For Patient Stratification and Therapeutic Selection". Blood 122, n.º 21 (15 de novembro de 2013): 5263. http://dx.doi.org/10.1182/blood.v122.21.5263.5263.
Texto completo da fonteFujita, M., K. Fukuda, S. Hayashi, K. Kikuchi, Y. Takashima, T. Kamenaga, T. Maeda, T. Matsubara e R. Kuroda. "AB0089 THE ANALYSIS FOR THE INHIBITION OF ANGIOGENESIS BY JAK INHIBITOR". Annals of the Rheumatic Diseases 79, Suppl 1 (junho de 2020): 1344.2–1344. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3161.
Texto completo da fonteSeverin, Frezzato, Visentin, Martini, Trimarco, Carraro, Tibaldi et al. "In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment". Cancers 11, n.º 12 (4 de dezembro de 2019): 1939. http://dx.doi.org/10.3390/cancers11121939.
Texto completo da fonteChen, Jing, Yong Zhang, Michael N. Petrus, Wenming Xiao, Alina Nicolae, Mark Raffeld, Stefania Pittaluga et al. "Cytokine receptor signaling is required for the survival of ALK− anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations". Proceedings of the National Academy of Sciences 114, n.º 15 (29 de março de 2017): 3975–80. http://dx.doi.org/10.1073/pnas.1700682114.
Texto completo da fonteVian, Laura, Mimi Lee, Giuseppe Sciumè, Nathalia Gazaniga, Stefania Dell'Orso, Stephen Brooks e Massimo Gadina. "Elucidating the role of cytokine signaling in the homeostasis of innate immune cells with JAK inhibitors". Journal of Immunology 202, n.º 1_Supplement (1 de maio de 2019): 181.27. http://dx.doi.org/10.4049/jimmunol.202.supp.181.27.
Texto completo da fonteHan, Yaguang, Yan Zhang, Ying Tian, Miao Zhang, Cheng Xiang, Qiang Zhen, Jiabao Liu et al. "The Interaction of the IFNγ/JAK/STAT1 and JAK/STAT3 Signalling Pathways in EGFR-Mutated Lung Adenocarcinoma Cells". Journal of Oncology 2022 (21 de setembro de 2022): 1–16. http://dx.doi.org/10.1155/2022/9016296.
Texto completo da fonte